NEW YORK (GenomeWeb News) – AB Sciex, Genedata, and LECO today announced a technology partnership to develop a collaborative software system to enable metabolomics researchers to comprehensively process and analyze experimental data across different GC/MS and LC/MS platforms.
The partnership brings together LECO's GC/MS expertise, AB Sciex's LC/MS expertise, and Genedata's experience in software development for drug discovery and life science research.
"The ability to bring data from different vendors and technologies onto a single platform, which can process and merge data for maximum biological inference, is where the industry needs to be to effectively evaluate the entire metabolome," Vladimir Tolstikov, scientist, Tailored Therapeutics at Eli Lilly, said in a statement commenting on the partnership.
The trio previously collaborated on the most recent version of Genedata's Expressionist MSX software, which was developed for metabolomics experiments performed with LECO and AB Sciex mass spec systems.
Financial and other terms of the agreement were not disclosed.